Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Follicular 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Non-Hodgkin 10Lymphoma 10Lymphoma, Mantle-Cell 7Recurrence 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Neoplasms 4Leukemia, B-Cell 3Neoplasm, Residual 2Burkitt Lymphoma 2Mature B-Cell Malignancies 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

tocilizumab 2talquetamab 1siltuximab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × obinutuzumab × 90 days × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡